Collaboration aims to accelerate clinical research and improve patient outcomes using advanced AI capabilities
Neurimmune and AICURA Medical GmbH today announced a strategic collaboration to harness the latest breakthroughs in artificial intelligence (AI) for the development of therapeutics for the treatment of Alzheimer’s disease. The partnership will leverage advanced AI systems to design clinical programs with the goal of improving patient outcomes and accelerating drug development timelines.
As part of the collaboration, AICURA and Neurimmune will develop and validate algorithms designed to predict disease status, responses to treatment and potential safety risks. These developments will be based on AICURA's AI capabilities and Neurimmune’s expertise in neurodegenerative diseases.
“Artificial intelligence can generate valuable insights to help develop targeted therapeutic solutions and guide clinical development of the next generation of treatments for patients with Alzheimer’s disease,” said Roger M. Nitsch, CEO & President of the Board of Neurimmune.
“Neurimmune is pioneering research & clinical development in neurodegenerative disease with an advancing pipeline of drug candidates and significant, multimodal data sets based on years of clinical research,” said Daniel Lichterfeld, CEO and Founder of AICURA Medical GmbH. “We look forward to collaborating with Neurimmune to unlock the full potential of its data to accelerate innovation and improve outcomes in Alzheimer’s disease.”
Based on results of the collaboration’s initial research phase, Neurimmune and AICURA have the option to extend the collaboration to develop, optimize, and commercialize software intended to be used for medical purposes (SaMDs) and drug development tools (DDTs) for neurodegenerative diseases to drive further innovations in the field of precision medicine.
About Neurimmune
Neurimmune is a biopharmaceutical company translating human immune memory into antibody therapeutics. Neurimmune develops drug candidates for CNS and related protein aggregation diseases including Alzheimer’s disease, amyotrophic lateral sclerosis, frontotemporal dementia and ATTR cardiomyopathy. With its Reverse Translational MedicineTM technology, Neurimmune discovered the brain amyloid depleter NI101SQ for Alzheimer’s disease, anti-SOD1 antibody AP-101 for ALS and the anti-ATTR antibody ALXN2220 (formerly NI006) for ATTR cardiomyopathy, programs currently in clinical development.
About AICURA medical GmbH
AICURA medical GmbH is a leading data and AI company specializing in healthcare and life sciences. Its mission is to enhance patient outcomes through a collaborative and secure data and AI ecosystem. AICURA’s platform enables data aggregation, exploration, curation, and analysis, supporting a wide range of stakeholders in the healthcare industry. The platform is powered by the AICURA Data Layer, which provides seamless integration, storage, and visualization of multimodal datasets, and the AICURA AI Engine, which facilitates rapid development and deployment of AI Systems for predictive models and advanced analytics. By connecting biotech firms, healthcare providers, Medtech companies, clinical researchers, and Contract Research Organizations (CROs), AICURA aims to establish a comprehensive ecosystem for data, technology, and knowledge transfer. This ecosystem has the potential to accelerate and scale data-driven research, streamline clinical trial design, de-risk drug development, improve patient care, and foster AI-based product innovation, paving the way for better treatment options.
Media Contacts
Neurimmune
John Capodanno (US)
john.capodanno@dentonsglobaladvisors.com
Martin Meier-Pfister (Switzerland)
media@neurimmune.com
AICURA Medical GmbH
Matteo Ugolini, PhD
matteo.ugolini@aicura-medical.com
